Items in cart [1] Questions? Call 888-624-8373

PAPERBACK list:$21.00 Web:$18.90 add to cart PDF BOOK your price: $16.50 add to cart Rights & Permissions Free Resources Display this book on your site! Related Titles The Threat of Pandemic Influenza: Are We Ready? Workshop Summary Immunization Safety Review: Vaccines and Autism Other Related Titles Vaccine Supply and Innovation (1985) Institute of Medicine (IOM) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 194   E-mail  Facebook  Digg  Stumble  Twitter More Page 194 Front Matter (R1-R12) 1 Summary (1-13) 2 Vaccines: Past, Present, and Future (14-26) 3 Vaccine Availability: Concerns, Barriers, and Impediments (27-44) 4 Economic Aspects of Vaccine Innovation and Manufacturing (45-64) 5 Vaccine Injury (65-84) 6 Liability for the Production and Sale of Vaccines (85-122) 7 An Approach to Problems of Communication, Coordination, and Collaboration in Vaccine Policy (123-135) 8 Vaccine Injury Compensation and Liability Remedies (136-160) Appendix A: Product License Holders (161-163) Appendix B: A Vaccine Supply Public Insurance Option (164-165) Appendix C: No-Fault Vaccine Injury Insurance (166-170) Appendix D: Injury Compensation Systems in the United States (171-175) Appendix E: Vaccine-Injury Compensation in Other Countries (176-182) Appendix F: Proposed Vaccine-Injury Compensation Systems (183-191) Appendix G: Mechanisms Used in Other Countries to Ensure Vaccine Supply (192-193) Appendix H: Background Papers (194-195) Appendix I: Biographical Notes on Committee Members and Consultants (196-200) Appendix J: Recommendations for the Proposed Vaccine Commission (201-202) Index (203-210)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 194
Appendix H BACKGROUND PAPERS Case Histories . . The Development of Pneumococcal Vaccine; Summary of Issues Affecting the Development and Utilization of Polyvalent Pneumococcal Vaccine by Robert Austrian, M.D. A Case History: Rubella Vaccine by Louis Z. Cooper, M.D. Issues Issues in the Production and Supply of Vaccines from Domestic Manufacturers and Foreign Sources by Hope E. Hopps, M.S. The Domestic Vaccine Industry: The Economic Framework by Lawrence M. DeBrock, Ph.D. Legal Issues Affecting the Development and Distribution of Vaccines by Richard F. Kingham, J.D. No-Fault Insurance for Vaccine Related Injuries by Jeffrey O'Connell, J.D. Formulating Recommendations on Immunization in the United States by H. Bruce Dull, M.D. Public Sector Perspectives The Interaction of Federal Agencies and Pharmaceutical Companies in Vaccine Development (NIAID) by William S. Jordan, Jr., M.D., and George J. Galasso, Ph.D. The Interaction of FDA and the Regulated Industry with Respect to Vaccine Development (FDA) by Paul D. Parkman, M.D., Hope E. Hopps, M.S., and Harry M. Meyer, Jr., M.D. Vaccine Development and Use: A CDC Perspective (CDC) by Gary R. Noble, M.D. and Alan R. Hinman, M.D. Impediments to the Development and Production of Immunogens of Interest to the Department of Defense (DOD) by David M. Robinson, D.V.M., Ph.D. Role of the Massachusetts Public Health Biologic Laboratories (Massachusetts) by George F. Grady, M.D. 194

OCR for page 195
195 Vaccine Development Incentives and Disincentives (Michigan) by John R. Mitchell, D.V.M., Dr.P.H. Private Sector Perspectives A Manufacturer's View of the Vaccine Market (Burroughs Wellcome) by Fred A. Coe, Jr. Issues in Vaccine Development from the Perspective of a "New Biotechnology Based Company" (Genentech) by David W. Martin, Jr., M.D. f An Overview of Factors Which May Impede Public-Private Sector Relationships Affecting Vaccine Development and Use (Merieux Institute) by Pinya Cohen, Ph.D. Government Industry Interaction and its Effect on the Biological Business (Lederle) by Francis R. Cano, Ph.D. Vaccine Innovation and the Private Sector (Eli Lilly) by Cornelius W Pettinga, Phi. . - Vaccine Development: An Industrial Point of View (Merck Sharp & Dohme) by Maurice R. Hilleman, Ph.D., D.Sc.

Representative terms from entire chapter:

pneumococcal vaccine